Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization

Life Sciences

Volumn 80, Issue 7, 2007, Pages 601-608

  Tang, Qizhu ^a   Huang, Ji ^a   Qian, Haiyan ^b   Chen, Li ^c   Wang, Teng ^a   Wang, Haining ^a   Shen, Difei ^a   Wu, Hui ^a   Xiong, Ran ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Action potential duration; Autoimmune myocarditis; HMG CoA reductase inhibitor; Inflammation; Potassium channels

Indexed keywords

ATORVASTATIN; CYTOKINE; GAMMA INTERFERON; ION CHANNEL; TUMOR NECROSIS FACTOR ALPHA;

ACTION POTENTIAL; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART REPOLARIZATION; MOUSE; MYOCARDITIS; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIA; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HEART; HEART VENTRICLES; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; PYRROLES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS;

EID: 33846221925     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.11.045     Document Type: Article

References (42)

1. Azuma R.W., Suzuki J., Ogawa M., Futamatsu H., Koga N., Onai Y., Kosuge H., and Isobe M. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovascular Research 64 (2004) 412-420
2. Bachmaier K., Pummerer C., Kozieradzki I., Pfeffer K., Mak T.W., Neu N., and Penninger J.M. Low-molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart disease. Circulation 95 (1997) 655-661
3. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circulation Research 73 (1993) 379-385
4. Black A.E., Sinz M.W., Hayes R.N., and Woolf T.F. Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metabolism and Disposition 26 (1998) 755-763
5. + current changes and action potential duration. Journal of the American College of Cardiology 41 (2003) 1611-1622
6. Bryant D., Becker L., Richardson J., Shelton J., Franco F., Peshock R., Thompson M., and Giroir B. Cardiac failure transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97 (1998) 1375-1381
7. Chen J., Nagasawa Y., Zhu B.M., Ohmori M., Harada K.I., Fujimura A., and Hashimoto K. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats. Journal of Pharmaceutical Sciences 93 (2003) 87-94
8. Cihakova D., Sharma R.B., Fairweather D., Afanasyeva M., and Rose N.R. Animal models for autoimmune myocarditis and autoimmune thyroiditis. In: Perl A. (Ed). Autoimmunity: methods and protocols (2004), Humana Press, New Jersey 175-193
9. De Sutter J., Tavernier R., De Buyzere M., Jordaens L., and De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. Journal of the American College of Cardiology 36 (2000) 766-772
10. Donermeyer D.L., Beisel K.W., Allen P.M., and Smith S.C. Myocarditis-inducing epitope of myosin binds constitutively and stably to I-A(k) on antigenpresenting cells in the heart. Journal of Experimental Medicine 182 (1995) 1291-1300
11. Eriksson U., Kurrer M.O., Sonderegger I., Iezzi G., Tafuri A., Hunziker L., Suzuki S., Bachmaier K., Bingisser R.M., Penninger J.M., and Kopf M. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. Journal of Experimental Medicine 197 (2003) 323-331
12. Eriksson U., Ricci R., Hunziker L., Kurrer M.O., Oudit G.Y., Watts T.H., Sonderegger I., Bachmaier K., Kopf M., and Penninger J.M. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nature Medicine 9 (2003) 1484-1490
13. Feldman A.M., and McNamara D. Myocarditis. New England Journal of Medicine 343 (2000) 1388-1398
14. Gegg M.E., Harry R., Hankey D., Zambarakji H., Gareth P., Baker D., Adamson P., Calder V., and Greenwood J. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. Journal of Immunology 174 (2005) 2327-2335
15. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. New England Journal of Medicine 319 (1988) 24-33
16. Hamill O.P., Marty A., Neher E., Sakmann S., and Sigworth F.J. Improved patch clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflugers Archiv 391 (1981) 85-100
17. Kawada H., Niwano S., Niwano H., Yumoto Y., Wakisaka Y., Yuge M., Kawahara K., and Izumi T. Tumor necrosis factor-α downregulates the voltage gated outward K+ current in cultured neonatal rat cardiomyoctes: a possible cause of electrical remodeling in diseased hearts. Circulation Journal 70 (2006) 605-609
18. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., Chia D., Terasaki P.I., Sabad A., Cogert G.A., Trosian K., Hamilton M.A., Moriguchi J.D., Kawata N., Hage A., Drinkwater D.C., and Stevenson L.W. Effect of pravastatin on outcomes after cardiac transplantation. New England Journal of Medicine 333 (1995) 621-627
19. Kodama M., Matsumoto Y., Fujiwara M., Masani F., and Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clinical Immunology and Immunopathology 57 (1990) 250-262
20. Kumagai K., Nakashima H., and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile percarditis model. Cardiovascular Research 62 (2004) 105-111
21. Kwak B., Mulhaupt F., Veillard N., and Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Medical Weekly 131 (2001) 41-46
22. Less H., Shilkrut M., Rubinstein I., Berke G., and Binah O. Cardiac dysfunction in murine autoimmune myocarditis. Journal of Autoimmunity 12 (1999) 209-220
23. Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., Madhok R., and Campbell C. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. Journal of Immunology 170 (2003) 1524-1530
24. Li W.M., Liu W., Gao C., and Zhou B.G. Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats. Immunology and Cell Biology 84 (2006) 274-280
25. Liao J.K. Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation 110 (2002) 285-288
26. Liu W., Li W.M., Gao C., and Sun N.L. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. Journal of Autoimmunity 25 (2005) 258-263
27. Mach F. Statins as immunomodulatory agents. Circulation 109 supplII (2004) II-15-II-17
28. Mitchell L.B., Powell J.L., Gillis A.M., Kehl V., Hallstrom A.P., and the AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. Journal of the American College of Cardiology 42 (2003) 81-87
29. Neu N., Rose N.R., Beisel K.W., Herskowitz A., Gurri G.G., and Craig S.W. Cardiac myosin induces myocarditis in genetically predisposed mice. Journal of Immunology 139 (1987) 3630-3636
30. Neumann D.A., Rose N.R., Ansari A.A., and Herskowitz A. Induction of multiple heart autoantibodies in mice with coxsackievirus B3-and cardiac myosin-induced autoimmune myocarditis. Journal of Immunology 152 (1994) 343-350
31. Oudit G.Y., Kassiri Z., Sah R., Ramirez R.J., Zobel C., and Backx P.H. The molecular physiology of the cardiac transient outward potassium current (Ito) in normal and diseased myocardium. Journal of Molecular and Cellular Cardiology 33 (2001) 851-872
32. Pummerer C.L., Grassl G., Sailer M., Bachmaier K.W., Penninger J.M., and Neu N. Cardiac myosin-induced myocarditis: target recognition by autoreactive T cells requires prior activation of cardiac interstitial cells. Laboratory Investigation 74 (1996) 845-852
33. Pummerer C.L., Luze K., Grässl G., Bachmaier K., Offner F., Burrell S.K., Lenz D.M., Zamborelli T.J., Penninger J.M., and Neu N. Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. Journal of Clinical Investigation 97 (1996) 2057-2062
34. Shiroshita-Takeshita A., Schram G., Lavoie J., and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
35. Smith S.C., and Allen P.M. Myosin-induced acute myocarditis is a T cell mediated disease. Journal of Immunology 147 (1991) 2141-2147
36. Smith S.C., and Allen P.M. Expression of myosin-class II major histocompatibility complexes in the normal myocardium occurs before induction of autoimmune myocarditis. Proceedings of the National Academy of Sciences of the United States of America 89 (1992) 9131-9135
37. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., and Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation 108 (2001) 1429-1437
38. Trepanier-Boulay V., St-Michel C., Tremblay A., and Fiset C. Gender-based differences in cardiac repolarization in mouse ventricle. Circulation Research 89 (2001) 437-444
39. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., and Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Medicine 7 (2001) 687-692
40. Wenke K., Meiser B., Thiery J., Nagel D., von Scheidt W., Steinbeck G., Seidel D., and Reichart B. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 96 (1997) 1398-1402
41. Young-Xu Y., Jabbour S., Goldberg R., Blatt C.M., Graboys T., Bilchik B., and Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. American Journal of Cardiology 92 (2003) 1379-1383
42. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., and Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78